Ruxolitinib is an Orally Active JAK1/2 Inhibitor for Multiple Myeloma Research
Multiple Myeloma (MM) is linked to the JAK1 and JAK2 genes in its development, similar to myelofibrosis. Myelofibrosis is a clonal disorder that starts at the hematopoietic stem cell level.…